Immunotherapy holds great promise for cancer treatment, but why some patients respond better to immunotherapy than others remains a mystery. To uncover the role of genomic heterogeneity in therapeutic efficacy, scientists combine whole genome sequencing of patient samples with machine learning and animal models. In this webinar, Kuan-lin Huang and Benjamin Ostendorf will discuss recent research insights into the contributions of genomic heterogeneity to immunotherapy responses and outcomes.
Topics to be covered
Speaker Information:
Kuan-lin Huang, PhD
Assistant Professor
Department of Genetics and Genomic Sciences
Mount Sinai Center for Transformative Disease Modeling
Icahn School of Medicine at Mount Sinai
Benjamin Ostendorf, MD, PhD
Max Eder Group Leader
Charité – Universitätsmedizin Berlin
Drug Discovery News
1000 N West Street | Wilmington | Delaware | 19801 | US
Email: privacy@drugdiscoverynews.com
© 2021 Old River Publications LLC. All rights reserved
Drug Discovery News needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy